Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores.

ABSTRACT:

Objective

To investigate the efficacy and safety of ticagrelor and different dosages of clopidogrel after acute coronary syndrome.

Methods

We compared different antiplatelet strategies for the prevention of cardiovascular events in 1939 patients admitted to the hospital with an acute coronary syndrome undergoing percutaneous coronary intervention (PCI).

Results

At 24 months, a survival analysis showed that ticagrelor and double-dose clopidogrel decreased the incidence of MACCE (a composite of all-cause death, myocardial infarction (MI), target vessel revascularization and stroke) (p < 0.001, p = 0.012, respectively). Although double-dose clopidogrel obviously increased the risk of major bleeding (p < 0.001), a similar result was not observed in the ticagrelor group (p

SUBMITTER: Xiao P 

PROVIDER: S-EPMC8322751 | biostudies-literature | 2021 May-Jun

REPOSITORIES: biostudies-literature